Cargando…
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
BACKGROUND: We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody) and selumetinib (MEK 1/2 inhibitor). METHODS: Patients with advanced solid tumours, refractory to standard therapy received selumetinib hydrogen sulphate ca...
Autores principales: | Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453594/ https://www.ncbi.nlm.nih.gov/pubmed/25268371 http://dx.doi.org/10.1038/bjc.2014.515 |
Ejemplares similares
-
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
por: Naing, A, et al.
Publicado: (2013) -
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
por: Qu, Xiao, et al.
Publicado: (2017) -
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
por: Chugh, R., et al.
Publicado: (2019) -
Cixutumumab reveals a critical role for IGF-1 in adipose and hepatic tissue remodelling during the development of diet-induced obesity
por: Imrie, Helen, et al.
Publicado: (2022) -
Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer
por: Solomon, Viswas Raja, et al.
Publicado: (2020)